inobrodib

News

CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.

News

Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.